References
- Hengstenberg C, Chandrasekhar J, Sartori S, et al. Impact of pre-existing or new-onset atrial fibrillation on 30-day clinical outcomes following transcatheter aortic valve replacement: results from the BRAVO 3 randomized trial. Catheter Cardiovasc Interv. 2017;90(6):1027–1037. doi:10.1002/ccd.v90.6.
- Sannino A, Stoler RC, Lima B, et al. Frequency of and prognostic significance of atrial fibrillation in patients undergoing transcatheter aortic valve implantation. Am J Cardiol. 2016;118(10):1527–1532. doi:10.1016/j.amjcard.2016.08.017.
- Barbash IM, Minha S, Ben-Dor I, et al. Predictors and clinical implications of atrial fibrillation in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation. Catheter Cardiovasc Interv. 2015;85(3):468–477. doi:10.1002/ccd.v85.3.
- Tarantini G, Mojoli M, Windecker S, et al. Prevalence and impact of atrial fibrillation in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: an analysis from the SOURCE XT prospective multicenter registry. JACC Cardiovasc Interv. 2016;9(9):937–946. doi:10.1016/j.jcin.2016.01.037.
- Vora AN, Dai D, Matsuoka R, et al. Incidence, management, and associated clinical outcomes of new-onset atrial fibrillation following transcatheter aortic valve replacement: an analysis from the STS/ACC TVT registry. JACC Cardiovasc Interv. 2018;11(17):1746–1756. doi:10.1016/j.jcin.2018.05.042.